Biotech
-
FDA meeting on flu vaccine composition is canceled
The meeting, which helps the FDA give guidance to vaccine makers on which flu strains to target, is the second…
Read More » -
Drug compounders sue FDA over declaration ending Wegovy shortage
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,”…
Read More » -
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a…
Read More » -
Advamed CEO warns FDA job cuts put patients, industry at risk
Scott Whitaker sent a letter to HHS calling for staff cuts at the FDA to be reversed, arguing patient care…
Read More » -
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public
Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public…
Read More » -
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager…
Read More » -
A brain biotech launches with Roche’s spare parts
Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan…
Read More » -
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a…
Read More » -
Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t…
Read More » -
Immune drugmakers Alumis and Acelyrin to merge
The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves…
Read More »